Effect of the dual endothelin receptor antagonist bosentan on untreatable skin ulcers in a patient with diabetes: a case report by Álvarez Reyes, Fátima et al.
CASE REPORT Open Access
Effect of the dual endothelin receptor antagonist
bosentan on untreatable skin ulcers in a patient
with diabetes: a case report
Fátima Álvarez Reyes
*, Cristina Luna Gómez and Manuel Brito Suárez
Abstract
Introduction: Refractory skin ulcers are a major burden in patients with diabetes. Their pathogenesis is
multifactorial, and data increasingly implicate endothelin as a mediator of diabetic macro- and microvasculopathy.
Here we describe the first reported case of an endothelin receptor antagonist being used to successfully treat
refractory skin ulcers in a patient with diabetes.
Case presentation: An 85-year-old Caucasian man with a 30-year history of type 2 diabetes developed multiple
skin ulcerations, including a right heel ulcer. Despite appropriate treatment, the ulcer showed little improvement
and the risk of amputation was high. The patient was treated with the dual endothelin receptor antagonist
bosentan. After three weeks of treatment, major improvements were observed, and after 21 weeks, all ulcers had
healed. No abnormalities were observed during monitoring of blood pressure, erythrocyte sedimentation rate or
serum aminotransferase levels.
Conclusion: In patients with refractory ulceration associated with diabetes, bosentan may be of real benefit,
especially in terms of amputation prevention. This case supports the proposed role for endothelin in the
pathogenesis of skin ulceration in diabetes and is suggestive of a potential benefit of bosentan in this patient type.
This case report is of interest to diabetologists and dermatologists.
Introduction
Non-healing skin ulcers, particularly those affecting the
heel, are major complications in diabetes and often lead
to amputation below the knee [1,2]. The pathogenesis of
these ulcerations is often multifactorial and includes
Macrovasculopathy (arterial insufficiency), microvasculo-
pathy (neuropathy and diabetic skin microangiopathy),
and an increased propensity for infection [3]. Endothelin
may underlie the development of vascular complications
in diabetes, and there is increasing evidence supporting
a role for endothelin early in the pathogenesis of dia-
betic micro- and Macrovasculopathy [4-6]. In this
report, we describe the successful use of bosentan, an
oral dual endothelin receptor antagonist [7], in a patient
with diabetes who had multiple non-healing skin ulcers,
including one that affected the heel.
Case presentation
Our patient was an 85-year-old Caucasian man with a
30-year history of type 2 diabetes. Sixteen years after
being diagnosed with hypertension following a stroke
that caused mild residual right hemiparesis, he was suc-
cessfully treated for prostate cancer with radiotherapy.
Ten years later an electromyogram showed mixed per-
ipheral polyneuropathy with axonal predominance.
While the patient was ambulatory, a 2 cm ulcer
appeared on his right heel after prolonged exposure to
heat, and it increased in size despite appropriate wound
care and glycemic control. Less than three months later
the patient was unable to walk and was subsequently
admitted to our hospital for congestive heart failure.
A skin examination performed at the time of admis-
sion showed the heel ulcer to be extensive (Figures 1A
and 1B), and it was evaluated as grade III according to
the Wagner grading system [8]. Three additional decubi-
tal lesions had developed on the sacral area, external
malleolus and flexure of the right ankle. These lesions
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any medium, provided the original work is properly cited.Figure 1 Ulcer status at presentation, after standard therapy and following treatment with bosentan. (A and B) Wagner grade III heel
ulcer on admission showing exposure of the calcaneus with an inflammatory aspect and very limited granulation tissue covered by purulent,
fetid exudates. (C and D) After three weeks of standard therapy, little improvement was observed, and after five months of conventional local
and systemic therapy, the ulcer remained at Wagner grade III, affecting the total posterior face with partial exposure of the calcaneus but
sparing the Achilles tendon. (E) Notable improvements were observed in the heel ulcer after the initiation of bosentan therapy and two weeks’
treatment at a maintenance dose, with marked granulation tissue apparent on the heel. (F) Complete healing of the ulcer was observed after a
total of 21 weeks of bosentan therapy.
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neated with a necrotic appearance, without granulation
tissue, and covered by purulent exudates.
A general examination indicated that the patient had
congestive heart failure probably due to ischemic heart
disease. Echocardiography was not performed, and elec-
trocardiography showed no evidence of myocardial
infarction. The patient’s diabetes was poorly controlled,
with neutral protamine Hagedorn insulin measurements
of 40 IU in the morning and 15 IU in the evening, and
glycosylated hemoglobin levels >8%, which required
adjustments of his insulin dose and addition of on-
demand fast-acting insulin. He was also receiving bicalu-
tamide 50 mg/day, candesartan 16 mg/day, furosemide
20 mg/day, triflusal 600 mg/day and calcium dobesilate
500 mg twice daily. These medications were continued
throughout the patient’s ulcer-specific treatment.
Treatment of the ulcer itself was initiated by the
patient’s general practitioner with oral ciprofloxacin 500
mg every 12 hours for two months. As a result of bac-
terial susceptibility testing, three months later antibiotic
treatment was continued with clavulanic acid plus
amoxicillin (875 mg three times daily) for 15 days. The
patient also received pentoxifylline (600 mg twice daily).
General wound care was applied with weekly gentle
mechanical and enzymatic debridement with Iruxol and
Intrasite hydrogel. His response to this initial treatment
was disappointing, and the heel ulcer remained at
Wagner grade III (Figures 1C and 1D). The three decu-
bital lesions remained at Wagner grade II. In parallel,
his general condition deteriorated, and vascular surgery
was contraindicated.
Investigation
Given the lack of response, risk of amputation, and gen-
eral deterioration in this patient’s condition, bosentan
was initiated on a compassionate use basis, with
informed consent, three months after his hospitalization.
Antibiotic therapy was discontinued and not reinstated
during the course of treatment with bosentan. Bosentan
has been shown to prevent the occurrence of new digital
ulcers in patients with systemic sclerosis and a history of
digital ulceration at a dose of 62.5 mg twice daily and
titrated up to 125 mg twice daily after four weeks [9].
However, given our patient’s age and history of cardio-
pathy, bosentan was initiated at a dose of 62.5 mg once
daily for one week and titrated up to a maintenance
dose of 62.5 mg every 12 hours twice daily thereafter.
Following a two-week treatment period at the mainte-
nance dose, all ulcers had improved and marked granu-
lation tissue was apparent on the heel ulcer (Figure 1E)
and the ulcer on the flexure of the right ankle. The
sacral and external malleolar ulcers had both healed
rapidly. The patient’s general condition improved in
parallel.
Following 21 weeks of bosentan treatment, the ulcer
on the flexure of the right ankle and the heel ulcer had
healed (Figure 1F), and the patient was able to walk
using a walking aid. His bosentan therapy was well-tol-
erated. Monitoring of blood pressure, erythrocyte sedi-
mentation rate, and alanine and aspartate
aminotransferase levels during treatment showed no
abnormalities. Bosentan was discontinued upon ulcer
healing with no relapse observed to date.
Discussion
The sequence of events observed in this patient suggests
a beneficial role for dual endothelin receptor antagon-
ism, as no other known or relevant therapeutic interven-
tion was initiated concomitant to treatment with
bosentan. However, as a single case report, several lim-
itations warrant acknowledgement. Wound healing is
influenced by multiple variables, and it was not possible
to strictly control for all potential confounders in this
case. In addition, there are limited data describing neu-
rological and cardiovascular status (for example, extent
of neuropathy, ankle-brachial index) available for this
patient. Furthermore, the etiology of these ulcers
appears intricate and may involve several pathological
processes. For example, neuropathy was documented by
electromyography and may be implicated in the expo-
sure to heat, which was considered the cause of the heel
ulcer. After the patient became unable to walk, the pres-
sure that caused the decubital lesions most likely perpe-
tuated all ulcers, and infection may have caused them,
too. Macrovasculopathy is also a possible contributory
factor to the lower-limb ulcers, and diabetic skin micro-
angiopathy should be regarded as a common underlying
cause for the appearance of all ulcers and their resis-
tance to standard therapy. Although our patient had
congestive heart failure and peripheral edema, these
occurred six weeks after the appearance of the ulcer
and, in our opinion, were not related to the develop-
ment of his lesions.
Having acknowledged these limitations, we think that
this case report adds to the increasing evidence in sup-
port of a key role for endothelin in the pathogenesis of
diabetic macro- and microangiopathy. Endothelin
plasma levels are elevated in patients with type 2 dia-
betes and correlate positively with diabetic vascular dis-
order [4,5], including diabetic skin microangiopathy,
which leads to the development of chronic foot ulcers.
Improvements in macro-vascular as well as microvascu-
lar functioning have been reported following the use of
endothelin receptor antagonists in animal models [5]
and in patients with diabetes[ 1 0 - 1 4 ] ,a n de n d o t h e l i n
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nutritive skin microcirculation. The observations in this
case, especially given the timing of improvement in rela-
tion to bosentan administration, could be explained by
the effect of bosentan on the diabetic skin microangio-
pathy, hence supporting a role for endothelin in its
pathogenesis [4-6]. The efficacy of dual endothelin
receptor antagonism has already been shown in other
manifestations of diabetic microangiopathy [4,5].
Although unlikely, the effects of bosentan on glycemic
control [14] and the wound-healing process [16] may
also have contributed to our patient’s outcome.
Conclusions
While the observations reported here should be inter-
preted with caution and need to be confirmed in a con-
trolled study, the sequence of events is suggestive of a
beneficial role for bosentan in our patient. These find-
ings are consistent with current knowledge on the role
of endothelin in vascular complications of diabetes and
s u p p o r tc o n t i n u e di n v e s t i g a t i o no fe n d o t h e l i ni nt h e
pathophysiology of untreatable skin ulcers as well as
other manifestations of diabetic microangiopathy. This
original case report will be of interest primarily to diabe-
tologists and dermatologists.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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